These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39290866)

  • 1. Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS.
    Peng Y; Zhou Y; Shu K; Jia X; Zhong Y
    Front Pharmacol; 2024; 15():1396378. PubMed ID: 39290866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system.
    Yu D; Cheng T; Liu T; Xu W; Liu D; Dai J; Cai S; Guan Y; Ye T; Cheng X
    Expert Opin Drug Saf; 2024 Aug; ():1-8. PubMed ID: 39157912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS).
    Peng Y; Zhou Y; Zhou X; Jia X; Zhong Y
    Expert Opin Drug Saf; 2024 Aug; ():1-9. PubMed ID: 39083396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.
    Wang Y; Liu X
    Front Pharmacol; 2024; 15():1392263. PubMed ID: 39193332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.
    Li L; Xu Q; Liu Y; Pang L; Cui Z; Lu Y
    Front Pharmacol; 2024; 15():1403988. PubMed ID: 39114358
    [No Abstract]   [Full Text] [Related]  

  • 8. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
    Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
    Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
    [No Abstract]   [Full Text] [Related]  

  • 9. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
    Xiong R; Lei J; Pan S; Zhang H; Tong Y; Wu W; Huang Y; Lai X
    Front Pharmacol; 2023; 14():1226086. PubMed ID: 37781705
    [No Abstract]   [Full Text] [Related]  

  • 10. Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database.
    Huang F; San X; Liu Q; Zhu H; Xu W
    Sci Rep; 2024 Mar; 14(1):7489. PubMed ID: 38553504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.
    Chen X; Jiang Y; Zhu H; Tian M
    Front Pharmacol; 2024; 15():1417661. PubMed ID: 39380910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors.
    Fujiwara M; Uchida M; Endo M; Goto M; Shimizu T
    Oncology; 2023; 101(5):343-348. PubMed ID: 36889294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of adverse events associated with pimavanserin using the FAERS database.
    Gu J; Qu Y; Shen Y; Zhou Q; Jiang Y; Zhu H
    J Affect Disord; 2024 Oct; 362():742-748. PubMed ID: 39029673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
    Zhao B; Fu Y; Cui S; Chen X; Liu S; Luo L
    Front Pharmacol; 2024; 15():1333662. PubMed ID: 38533254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.